Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study - PubMed (original) (raw)
Clinical Trial
. 2010 Nov 20;28(33):4969-75.
doi: 10.1200/JCO.2009.27.8861. Epub 2010 Oct 4.
Wendy B London, Stephen D Gillies, Jacquelyn A Hank, Stephan D Voss, Robert C Seeger, C Patrick Reynolds, Jennifer Kimball, Mark R Albertini, Barrett Wagner, Jacek Gan, Jens Eickhoff, Kenneth B DeSantes, Susan L Cohn, Toby Hecht, Brian Gadbaw, Ralph A Reisfeld, John M Maris, Paul M Sondel
Affiliations
- PMID: 20921469
- PMCID: PMC3020698
- DOI: 10.1200/JCO.2009.27.8861
Clinical Trial
Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study
Suzanne Shusterman et al. J Clin Oncol. 2010.
Abstract
Purpose: The hu14.18-IL2 fusion protein consists of interleukin-2 molecularly linked to a humanized monoclonal antibody that recognizes the GD2 disialoganglioside expressed on neuroblastoma cells. This phase II study assessed the antitumor activity of hu14.18-IL2 in two strata of patients with recurrent or refractory neuroblastoma.
Patients and methods: Hu14.18-IL2 was given intravenously (12 mg/m(2)/daily) for 3 days every 4 weeks for patients with disease measurable by standard radiographic criteria (stratum 1) and for patients with disease evaluable only by [(123)I]metaiodobenzylguanidine (MIBG) scintigraphy and/or bone marrow (BM) histology (stratum 2). Response was established by independent radiology review as well as BM histology and immunocytology, and durability was assessed by repeat evaluation after more than 3 weeks.
Results: Thirty-nine patients were enrolled (36 evaluable). No responses were seen in stratum 1 (n = 13). Of 23 evaluable patients in stratum 2, five patients (21.7%) responded; all had a complete response (CR) of 9, 13, 20, 30, and 35+ months duration. Grade 3 and 4 nonhematologic toxicities included capillary leak, hypoxia, pain, rash, allergic reaction, elevated transaminases, and hyperbilirubinemia. Two patients required dopamine for hypotension, and one patient required ventilatory support for hypoxia. Most toxicities were reversible within a few days of completing a treatment course and were expected based on phase I results.
Conclusion: Patients with disease evaluable only by MIBG and/or BM histology had a 21.7% CR rate to hu14.8-IL2, whereas patients with bulky disease did not respond. Hu14.18-IL2 warrants further testing in children with nonbulky high-risk neuroblastoma.
Conflict of interest statement
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
Figures
Fig 1.
(A) Event-free survival (EFS) and overall survival (OS) for all patients; (B) EFS for stratum 1 and stratum 2; (C) OS for stratum 1 and stratum 2. The numbers alongside each curve, at the 1-year time point, indicate the number of patients corresponding to that curve at the 1-year time point.
Fig A1.
Absolute lymphocyte counts obtained for each course. For each course, the absolute lymphocyte count (lymphocytes/μL × 10_3_) were measured in peripheral blood on day 1 (just before starting the day 1 infusion of hu14.18-IL2), on day 3 (just before starting the day 3 infusion of hu14.18-IL2), on day 4 (20 hours after completing the day 3 hu14.18-IL2 infusion), and on day 8 (5 days after completing the day 3 hu14.18-IL2 infusion). The transient lymphopenia seen on days 3 and 4 is more severe for courses 1 and 2. By day 8, for each course, there is a prominent lymphocytosis. Data shown are the means for all treated patients.
Similar articles
- Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study.
Shusterman S, Naranjo A, Van Ryn C, Hank JA, Parisi MT, Shulkin BL, Servaes S, London WB, Shimada H, Gan J, Gillies SD, Maris JM, Park JR, Sondel PM. Shusterman S, et al. Clin Cancer Res. 2019 Oct 15;25(20):6044-6051. doi: 10.1158/1078-0432.CCR-19-0798. Epub 2019 Jul 29. Clin Cancer Res. 2019. PMID: 31358541 Free PMC article. Clinical Trial. - A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.
Osenga KL, Hank JA, Albertini MR, Gan J, Sternberg AG, Eickhoff J, Seeger RC, Matthay KK, Reynolds CP, Twist C, Krailo M, Adamson PC, Reisfeld RA, Gillies SD, Sondel PM; Children's Oncology Group. Osenga KL, et al. Clin Cancer Res. 2006 Mar 15;12(6):1750-9. doi: 10.1158/1078-0432.CCR-05-2000. Clin Cancer Res. 2006. PMID: 16551859 Free PMC article. Clinical Trial. - Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma.
Hank JA, Gan J, Ryu H, Ostendorf A, Stauder MC, Sternberg A, Albertini M, Lo KM, Gillies SD, Eickhoff J, Sondel PM. Hank JA, et al. Clin Cancer Res. 2009 Sep 15;15(18):5923-30. doi: 10.1158/1078-0432.CCR-08-2963. Epub 2009 Sep 8. Clin Cancer Res. 2009. PMID: 19737959 Free PMC article. - Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
Parsons K, Bernhardt B, Strickland B. Parsons K, et al. Ann Pharmacother. 2013 Feb;47(2):210-8. doi: 10.1345/aph.1R353. Epub 2013 Feb 5. Ann Pharmacother. 2013. PMID: 23386066 Review. - The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma.
Yamane BH, Hank JA, Albertini MR, Sondel PM. Yamane BH, et al. Expert Opin Investig Drugs. 2009 Jul;18(7):991-1000. doi: 10.1517/13543780903048911. Expert Opin Investig Drugs. 2009. PMID: 19548853 Free PMC article. Review.
Cited by
- Intratumoral injection and retention hold promise to improve cytokine therapies for cancer.
Sauer K, Rakhra K, Wu K, Mehta NK, Michaelson JS, Baeuerle PA. Sauer K, et al. Front Oncol. 2024 Aug 26;14:1456658. doi: 10.3389/fonc.2024.1456658. eCollection 2024. Front Oncol. 2024. PMID: 39252938 Free PMC article. - Stimulating the Antitumor Immune Response Using Immunocytokines: A Preclinical and Clinical Overview.
Boersma B, Poinot H, Pommier A. Boersma B, et al. Pharmaceutics. 2024 Jul 24;16(8):974. doi: 10.3390/pharmaceutics16080974. Pharmaceutics. 2024. PMID: 39204319 Free PMC article. Review. - IL-2 based cancer immunotherapies: an evolving paradigm.
Rokade S, Damani AM, Oft M, Emmerich J. Rokade S, et al. Front Immunol. 2024 Jul 24;15:1433989. doi: 10.3389/fimmu.2024.1433989. eCollection 2024. Front Immunol. 2024. PMID: 39114660 Free PMC article. Review. - GD2-targeting therapy: a comparative analysis of approaches and promising directions.
Philippova J, Shevchenko J, Sennikov S. Philippova J, et al. Front Immunol. 2024 Mar 15;15:1371345. doi: 10.3389/fimmu.2024.1371345. eCollection 2024. Front Immunol. 2024. PMID: 38558810 Free PMC article. Review. - Neuroblastoma: an ongoing cold front for cancer immunotherapy.
Kennedy PT, Zannoupa D, Son MH, Dahal LN, Woolley JF. Kennedy PT, et al. J Immunother Cancer. 2023 Nov 22;11(11):e007798. doi: 10.1136/jitc-2023-007798. J Immunother Cancer. 2023. PMID: 37993280 Free PMC article. Review.
References
- Maris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma. Lancet. 2007;369:2106–2120. - PubMed
- Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999;341:1165–1173. - PubMed
- Mujoo K, Spiro RC, Reisfeld RA. Characterization of a unique glycoprotein antigen expressed on the surface of human neuroblastoma cells. J Biol Chem. 1986;261:10299–10305. - PubMed
- Cheung NK, Saarinen UM, Neely JE, et al. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res. 1985;45:2642–2649. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- M01 RR003186/RR/NCRR NIH HHS/United States
- R01-CA-32685-25/CA/NCI NIH HHS/United States
- P01 CA081403/CA/NCI NIH HHS/United States
- U10CA98543/CA/NCI NIH HHS/United States
- RR03186/RR/NCRR NIH HHS/United States
- CA81403/CA/NCI NIH HHS/United States
- U10 CA098543/CA/NCI NIH HHS/United States
- R01 CA087025/CA/NCI NIH HHS/United States
- R01 CA032685/CA/NCI NIH HHS/United States
- U10 CA98413/CA/NCI NIH HHS/United States
- U10 CA098413/CA/NCI NIH HHS/United States
- CA87025/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical